Induction Chemotherapy followed by Hyperfractionated Radiotherapy with Concurrent Chemotherapy for Locally Advanced Head and Neck Cancer

Kumiko Karasawa, Hirofumi Shinoda, Kuniaki Katsui, Kaori Seki, Mari Kohno, Nahoko Hanyu, Sachiko Nasu, Hiroyuki Muramatsu, Katsuya Maebayashi, Norio Mitsuhashi, Toshio Yoshihara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The aim of this study was to improve tumor control, the survival rate and organ preservation for locally advanced head and neck cancer by using induction chemotherapy followed by hyperfractionated radiotherapy and concurrent chemotherapy. Materials and Methods: Thirty-five patients with stage III-IVB head and neck cancer were treated with this protocol, Induction chemotherapy consisted of cisplatin and fluorouracil and concurrent chemotherapy consisted of carboplatin and doxifluridin. Radiotherapy was administered twice a day until a dose of 72 Gy was reached. Results: Twenty-two (63%) and 13 patients (37%) achieved complete responses and partial responses, respectively. In terms of non-hematological toxicities, grade 3 mucositis was observed in 49 % of the patients. The overall 5-year survival was 53.5 % and the progression-free survival was 40.6 %. Conclusion: Response to induction chemotherapy was useful as a predictive factor for ultimate outcome and organ conservation. More intensive regimen or other combination chemotherapy is needed to improve treatment outcome with hyperfractionated radiotherapy.

Original languageEnglish
Pages (from-to)5031-5036
Number of pages6
JournalAnticancer Research
Volume23
Issue number6 D
Publication statusPublished - Nov 2003

Fingerprint

Induction Chemotherapy
Head and Neck Neoplasms
Radiotherapy
Drug Therapy
Organ Preservation
Mucositis
Carboplatin
Combination Drug Therapy
Fluorouracil
Cisplatin
Disease-Free Survival
Survival Rate
Survival
Neoplasms

Keywords

  • Chemoradiotherapy
  • Concurrent chemotherapy
  • Head and neck cancer
  • Hyperfractionated radiotherapy
  • Induction chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Induction Chemotherapy followed by Hyperfractionated Radiotherapy with Concurrent Chemotherapy for Locally Advanced Head and Neck Cancer. / Karasawa, Kumiko; Shinoda, Hirofumi; Katsui, Kuniaki; Seki, Kaori; Kohno, Mari; Hanyu, Nahoko; Nasu, Sachiko; Muramatsu, Hiroyuki; Maebayashi, Katsuya; Mitsuhashi, Norio; Yoshihara, Toshio.

In: Anticancer Research, Vol. 23, No. 6 D, 11.2003, p. 5031-5036.

Research output: Contribution to journalArticle

Karasawa, K, Shinoda, H, Katsui, K, Seki, K, Kohno, M, Hanyu, N, Nasu, S, Muramatsu, H, Maebayashi, K, Mitsuhashi, N & Yoshihara, T 2003, 'Induction Chemotherapy followed by Hyperfractionated Radiotherapy with Concurrent Chemotherapy for Locally Advanced Head and Neck Cancer', Anticancer Research, vol. 23, no. 6 D, pp. 5031-5036.
Karasawa, Kumiko ; Shinoda, Hirofumi ; Katsui, Kuniaki ; Seki, Kaori ; Kohno, Mari ; Hanyu, Nahoko ; Nasu, Sachiko ; Muramatsu, Hiroyuki ; Maebayashi, Katsuya ; Mitsuhashi, Norio ; Yoshihara, Toshio. / Induction Chemotherapy followed by Hyperfractionated Radiotherapy with Concurrent Chemotherapy for Locally Advanced Head and Neck Cancer. In: Anticancer Research. 2003 ; Vol. 23, No. 6 D. pp. 5031-5036.
@article{171f24e0da804471b2b5f742075ed8ad,
title = "Induction Chemotherapy followed by Hyperfractionated Radiotherapy with Concurrent Chemotherapy for Locally Advanced Head and Neck Cancer",
abstract = "Background: The aim of this study was to improve tumor control, the survival rate and organ preservation for locally advanced head and neck cancer by using induction chemotherapy followed by hyperfractionated radiotherapy and concurrent chemotherapy. Materials and Methods: Thirty-five patients with stage III-IVB head and neck cancer were treated with this protocol, Induction chemotherapy consisted of cisplatin and fluorouracil and concurrent chemotherapy consisted of carboplatin and doxifluridin. Radiotherapy was administered twice a day until a dose of 72 Gy was reached. Results: Twenty-two (63{\%}) and 13 patients (37{\%}) achieved complete responses and partial responses, respectively. In terms of non-hematological toxicities, grade 3 mucositis was observed in 49 {\%} of the patients. The overall 5-year survival was 53.5 {\%} and the progression-free survival was 40.6 {\%}. Conclusion: Response to induction chemotherapy was useful as a predictive factor for ultimate outcome and organ conservation. More intensive regimen or other combination chemotherapy is needed to improve treatment outcome with hyperfractionated radiotherapy.",
keywords = "Chemoradiotherapy, Concurrent chemotherapy, Head and neck cancer, Hyperfractionated radiotherapy, Induction chemotherapy",
author = "Kumiko Karasawa and Hirofumi Shinoda and Kuniaki Katsui and Kaori Seki and Mari Kohno and Nahoko Hanyu and Sachiko Nasu and Hiroyuki Muramatsu and Katsuya Maebayashi and Norio Mitsuhashi and Toshio Yoshihara",
year = "2003",
month = "11",
language = "English",
volume = "23",
pages = "5031--5036",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 D",

}

TY - JOUR

T1 - Induction Chemotherapy followed by Hyperfractionated Radiotherapy with Concurrent Chemotherapy for Locally Advanced Head and Neck Cancer

AU - Karasawa, Kumiko

AU - Shinoda, Hirofumi

AU - Katsui, Kuniaki

AU - Seki, Kaori

AU - Kohno, Mari

AU - Hanyu, Nahoko

AU - Nasu, Sachiko

AU - Muramatsu, Hiroyuki

AU - Maebayashi, Katsuya

AU - Mitsuhashi, Norio

AU - Yoshihara, Toshio

PY - 2003/11

Y1 - 2003/11

N2 - Background: The aim of this study was to improve tumor control, the survival rate and organ preservation for locally advanced head and neck cancer by using induction chemotherapy followed by hyperfractionated radiotherapy and concurrent chemotherapy. Materials and Methods: Thirty-five patients with stage III-IVB head and neck cancer were treated with this protocol, Induction chemotherapy consisted of cisplatin and fluorouracil and concurrent chemotherapy consisted of carboplatin and doxifluridin. Radiotherapy was administered twice a day until a dose of 72 Gy was reached. Results: Twenty-two (63%) and 13 patients (37%) achieved complete responses and partial responses, respectively. In terms of non-hematological toxicities, grade 3 mucositis was observed in 49 % of the patients. The overall 5-year survival was 53.5 % and the progression-free survival was 40.6 %. Conclusion: Response to induction chemotherapy was useful as a predictive factor for ultimate outcome and organ conservation. More intensive regimen or other combination chemotherapy is needed to improve treatment outcome with hyperfractionated radiotherapy.

AB - Background: The aim of this study was to improve tumor control, the survival rate and organ preservation for locally advanced head and neck cancer by using induction chemotherapy followed by hyperfractionated radiotherapy and concurrent chemotherapy. Materials and Methods: Thirty-five patients with stage III-IVB head and neck cancer were treated with this protocol, Induction chemotherapy consisted of cisplatin and fluorouracil and concurrent chemotherapy consisted of carboplatin and doxifluridin. Radiotherapy was administered twice a day until a dose of 72 Gy was reached. Results: Twenty-two (63%) and 13 patients (37%) achieved complete responses and partial responses, respectively. In terms of non-hematological toxicities, grade 3 mucositis was observed in 49 % of the patients. The overall 5-year survival was 53.5 % and the progression-free survival was 40.6 %. Conclusion: Response to induction chemotherapy was useful as a predictive factor for ultimate outcome and organ conservation. More intensive regimen or other combination chemotherapy is needed to improve treatment outcome with hyperfractionated radiotherapy.

KW - Chemoradiotherapy

KW - Concurrent chemotherapy

KW - Head and neck cancer

KW - Hyperfractionated radiotherapy

KW - Induction chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=10744229308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744229308&partnerID=8YFLogxK

M3 - Article

C2 - 14981963

AN - SCOPUS:10744229308

VL - 23

SP - 5031

EP - 5036

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 D

ER -